CStone Pharmaceuticals (CStone Pharma, HKEX: 02616) has filed its Monthly Return for the period ended 30 June 2026, confirming no changes in authorised or issued share capital while detailing continued share-based incentive activity and fresh buy-backs awaiting cancellation.

Authorised and Issued Share Capital • Authorised share capital remained at 2.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 0.20 million. • Issued share count stayed unchanged at 1.60 billion shares; no treasury shares are outstanding. • The company affirmed compliance with the Hong Kong Exchange’s 25% minimum public-float requirement.

Share-Based Incentive Schemes • Pre-IPO Incentivization Plan: 1.16 million options were outstanding at month-end, unchanged from May; no new shares were issued. • Post-IPO Employee Share Option Plan: Outstanding options fell by 206,922 to 104.83 million due to lapses. Shares that could be issued on exercise total 34.81 million, with 22.03 million additional options still available for future grants. • No warrant exercises, convertible issuances or other equity-linked instruments were reported during the month.

Share Repurchases • Under mandates approved on 25 June 2025 and 23 June 2026, the company repurchased 3.34 million and 1.26 million shares, respectively, between 15–22 June 2026 and 24–26 June 2026. • All 4.60 million repurchased shares remain outstanding but are earmarked for cancellation; consequently, month-end issued and treasury share balances were unchanged.

Liquidity and Capital Position • With no new shares issued or cancelled, cash proceeds from option exercises were HKD 0 for the month. • The absence of treasury stock at period-end leaves CStone Pharma’s capital structure stable ahead of the formal cancellation of the repurchased shares.

Compliance Statement The filing includes management’s confirmation that all transactions were duly approved, executed in accordance with Hong Kong listing rules, and that requisite public-float thresholds were met.